These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20190467)

  • 61. The effect of menaquinone-7 (vitamin K2) supplementation on osteocalcin carboxylation in healthy prepubertal children.
    van Summeren MJ; Braam LA; Lilien MR; Schurgers LJ; Kuis W; Vermeer C
    Br J Nutr; 2009 Oct; 102(8):1171-8. PubMed ID: 19450370
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Undercarboxylated osteocalcin concentration in postmenopausal women receiving hormone therapy daily and on alternate days.
    Yasui T; Uemura H; Umino Y; Yamada M; Kuwahara A; Matsuzaki T; Maegawa M; Furumoto H; Miura M; Irahara M
    Menopause; 2006; 13(2):314-22. PubMed ID: 16645545
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of risedronate on bone in renal transplant recipients.
    Coco M; Pullman J; Cohen HW; Lee S; Shapiro C; Solorzano C; Greenstein S; Glicklich D
    J Am Soc Nephrol; 2012 Aug; 23(8):1426-37. PubMed ID: 22797188
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome.
    Takei T; Itabashi M; Tsukada M; Sugiura H; Moriyama T; Kojima C; Shiohira S; Shimizu A; Karasawa K; Amemiya N; Kawanishi K; Ogawa T; Uchida K; Tsuchiya K; Nitta K
    Intern Med; 2010; 49(19):2065-70. PubMed ID: 20930431
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Serum undercarboxylated osteocalcin as biomarker of vitamin K intake and risk of prostate cancer: a nested case-control study in the Heidelberg cohort of the European prospective investigation into cancer and nutrition.
    Nimptsch K; Rohrmann S; Nieters A; Linseisen J
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):49-56. PubMed ID: 19124480
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of the effect of vitamin K(2) and risedronate on trabecular bone in glucocorticoid-treated rats: a bone histomorphometry study.
    Iwamoto J; Matsumoto H; Tadeda T; Sato Y; Yeh JK
    Yonsei Med J; 2009 Apr; 50(2):189-94. PubMed ID: 19430549
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impaired gamma carboxylation of osteocalcin in elderly women with type II diabetes mellitus: relationship between increase in undercarboxylated osteocalcin levels and low bone mineral density.
    Horiuchi T; Kazama H; Araki A; Inoue J; Hosoi T; Onouchi T; Mizuno S; Ito H; Orimo H
    J Bone Miner Metab; 2004; 22(3):236-40. PubMed ID: 15108065
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study).
    Schafer AL; Sellmeyer DE; Schwartz AV; Rosen CJ; Vittinghoff E; Palermo L; Bilezikian JP; Shoback DM; Black DM
    J Clin Endocrinol Metab; 2011 Dec; 96(12):E1982-9. PubMed ID: 21994958
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
    Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women.
    Szulc P; Chapuy MC; Meunier PJ; Delmas PD
    J Clin Invest; 1993 Apr; 91(4):1769-74. PubMed ID: 8473517
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Relationships between undercarboxylated osteocalcin and vitamin K intakes, bone turnover, and bone mineral density in healthy women.
    Yamauchi M; Yamaguchi T; Nawata K; Takaoka S; Sugimoto T
    Clin Nutr; 2010 Dec; 29(6):761-5. PubMed ID: 20332058
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Clinical implications of undercarboxylated osteocalcin].
    Hosoi T
    Clin Calcium; 2009 Dec; 19(12):1815-21. PubMed ID: 19949273
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Higher serum undercarboxylated osteocalcin and other bone turnover markers are associated with reduced diabetes risk and lower estradiol concentrations in older men.
    Yeap BB; Alfonso H; Chubb SA; Gauci R; Byrnes E; Beilby JP; Ebeling PR; Handelsman DJ; Allan CA; Grossmann M; Norman PE; Flicker L
    J Clin Endocrinol Metab; 2015 Jan; 100(1):63-71. PubMed ID: 25365314
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Serum percentage undercarboxylated osteocalcin, a sensitive measure of vitamin K status, and its relationship to bone health indices in Danish girls.
    O'Connor E; Mølgaard C; Michaelsen KF; Jakobsen J; Lamberg-Allardt CJ; Cashman KD
    Br J Nutr; 2007 Apr; 97(4):661-6. PubMed ID: 17349078
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The association between dietary vitamin K intake and serum undercarboxylated osteocalcin is modulated by vitamin K epoxide reductase genotype.
    Nimptsch K; Nieters A; Hailer S; Wolfram G; Linseisen J
    Br J Nutr; 2009 Jun; 101(12):1812-20. PubMed ID: 19025725
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Assessment of Biochemical Bone Turnover Markers and Bone Mineral Density in Thin and Normal-Weight Children.
    Ambroszkiewicz J; Gajewska J; Rowicka G; Klemarczyk W; Chelchowska M
    Cartilage; 2018 Jul; 9(3):255-262. PubMed ID: 29156943
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
    Racewicz AJ; Schofield PJ; Cahall DL; Cline GA; Burgio DE
    Curr Med Res Opin; 2007 Dec; 23(12):3079-89. PubMed ID: 17971285
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
    Shiraki M; Fukunaga M; Kushida K; Kishimoto H; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H
    Osteoporos Int; 2003 May; 14(3):225-34. PubMed ID: 12730746
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis.
    Iwasaki T; Nonoda Y; Ishii M
    Curr Med Res Opin; 2012 May; 28(5):737-47. PubMed ID: 22126423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.